Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26557
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McCullough PA | - |
dc.contributor.author | Alexander PE | - |
dc.contributor.author | Armstrong R | - |
dc.contributor.author | Arvinte C | - |
dc.contributor.author | Bain AF | - |
dc.contributor.author | Bartlett RP | - |
dc.contributor.author | Berkowitz RL | - |
dc.contributor.author | Berry AC | - |
dc.contributor.author | Borody TJ | - |
dc.contributor.author | Brewer JH | - |
dc.contributor.author | Brufsky AM | - |
dc.contributor.author | Clarke T | - |
dc.contributor.author | Derwand R | - |
dc.contributor.author | Eck A | - |
dc.contributor.author | Eck J | - |
dc.contributor.author | Eisner RA | - |
dc.contributor.author | Fareed GC | - |
dc.contributor.author | Farella A | - |
dc.contributor.author | Fonseca SNS | - |
dc.contributor.author | Geyer CE | - |
dc.contributor.author | Gonnering RS | - |
dc.contributor.author | Graves KE | - |
dc.contributor.author | Gross KBV | - |
dc.contributor.author | Hazan S | - |
dc.contributor.author | Held KS | - |
dc.contributor.author | Hight HT | - |
dc.contributor.author | Immanuel S | - |
dc.contributor.author | Jacobs MM | - |
dc.contributor.author | Ladapo JA | - |
dc.contributor.author | Lee LH | - |
dc.contributor.author | Littell J | - |
dc.contributor.author | Lozano I | - |
dc.contributor.author | Mangat HS | - |
dc.contributor.author | Marble B | - |
dc.contributor.author | McKinnon JE | - |
dc.contributor.author | Merritt LD | - |
dc.contributor.author | Orient JM | - |
dc.contributor.author | Oskoui R | - |
dc.contributor.author | Pompan DC | - |
dc.contributor.author | Procter BC | - |
dc.contributor.author | Prodromos C | - |
dc.contributor.author | Rajter JC | - |
dc.contributor.author | Rajter J-J | - |
dc.contributor.author | Ram CVS | - |
dc.contributor.author | Rios SS | - |
dc.contributor.author | Risch HA | - |
dc.contributor.author | Robb MJA | - |
dc.contributor.author | Rutherford M | - |
dc.contributor.author | Scholz M | - |
dc.contributor.author | Singleton MM | - |
dc.contributor.author | Tumlin JA | - |
dc.contributor.author | Tyson BM | - |
dc.contributor.author | Urso RG | - |
dc.contributor.author | Victory K | - |
dc.contributor.author | Vliet EL | - |
dc.contributor.author | Wax CM | - |
dc.contributor.author | Wolkoff AG | - |
dc.contributor.author | Wooll V | - |
dc.contributor.author | Zelenko V | - |
dc.date.accessioned | 2021-06-09T16:16:03Z | - |
dc.date.available | 2021-06-09T16:16:03Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 2153-8174 | - |
dc.identifier.issn | 2153-8174 | - |
dc.identifier.uri | http://hdl.handle.net/11375/26557 | - |
dc.description.abstract | The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death. | - |
dc.publisher | IMR Press | - |
dc.rights.uri | 2 | - |
dc.subject | COVID-19 | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | ambulatory treatment | - |
dc.subject | anti-infective | - |
dc.subject | anti-inflammatory | - |
dc.subject | anticoagulant | - |
dc.subject | antiplatelet agent | - |
dc.subject | antiviral | - |
dc.subject | corticosteroid | - |
dc.subject | hospitalization | - |
dc.subject | mortality | - |
dc.subject | sequenced multidrug therapy | - |
dc.subject | COVID-19 | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Humans | - |
dc.subject | Leprostatic Agents | - |
dc.subject | Pandemics | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | Telemedicine | - |
dc.title | Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) | - |
dc.type | Article | - |
dc.date.updated | 2021-06-09T16:16:03Z | - |
dc.rights.license | Attribution - CC BY | - |
dc.identifier.doi | https://doi.org/10.31083/j.rcm.2020.04.264 | - |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).pdf | Published version | 838.72 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.